111In-labeled site-specifically conjugated anti-PSMA antibody (Synaffix)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug Name111In-labeled site-specifically conjugated anti-PSMA antibody (Synaffix)
Drug Alias Name111In-DTPA-D2B-DAR2-MMAE111In-labeled site-specifically conjugated anti-PSMA antibody (SynAffix)111In-DTPA-D2B-DAR4-MMAE
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)Radiation-emitting products
Mechanisms of ActionProstate-Specific Membrane Antigen inhibitors
TargetsProstate-Specific Membrane Antigen
Therapy Area/IndicationsProstatic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryNetherlands
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesSynaffix BV
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSynaffix BV
Active IndicationsN/A
Inactive IndicationsProstatic Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A